Skip to main content

Table 2 Data used in network meta-analysis

From: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Study Dasatinib Nilotinib 600 mg Nilotinib 800 mg Imatinib 400 mg Imatinib 800 mg
Complete cytogenic response
6 months      
DASISION 73.0%    59.2%  
ENESTed   67.0% 63.0% 44.9%  
Baccarani et al.     50.0% 51.9%
German CML Study IV     21.5% 33.5%
Cortes et al. 2010     44.6% 56.7%
ISTAHIT     19.8% 43.8%
SPIRIT     50.0% 69.0%
12 months      
DASISION study group 83.4%    71.5%  
ENESTed study group   80.1% 77.9% 65.0%  
Baccarani et al. (2009)     58.3% 63.9%
German CML Study IV     49.8% 63.2%
Cortes et al. 2010     65.6% 69.9%
S0325 Intergroup Trial 82.0%    69.0%  
SPIRIT     58.0% 65.0%
18 months      
Dasatinib Study Group 88.6%     
DASISION study group 78.0%    70.0%  
ENESTed study group   85.0% 82.0% 74.0%  
German CML Study IV     66.6% 73.8%
Major Molecular response
12 months      
Bacarrani et al. (2009)     33.3% 39.8%
DASISION study group 45.9%    28.1%  
ENESTed Study group   44.0% 43.1% 21.9%  
German CML Study IV     30.8% 54.8%
Cortes et al. 2010     40.1% 46.4%
SPIRIT     38.0% 49.0%
S0325 Intergroup Trial 59.0%    43.0%